EMR Q1 2026 Earnings
Reported Feb 3, 2026 at 4:05 PM ET · SEC Source
Q1 26 EPS
$1.46
BEAT +3.39%
Est. $1.41
Q1 26 Revenue
$4.35B
MISS 0.06%
Est. $4.35B
vs S&P Since Q1 26
-17.3%
TRAILING MARKET
EMR -12.3% vs S&P +5.0%
Market Reaction
Did EMR Beat Earnings? Q1 2026 Results
Emerson Electric delivered a profitability beat in fiscal Q1 2026, with adjusted EPS of $1.46 clearing the $1.41 consensus estimate by 3.39%, even as net sales of $4.35 billion came in essentially flat against expectations, up 4.1% year-over-year. Th… Read more Emerson Electric delivered a profitability beat in fiscal Q1 2026, with adjusted EPS of $1.46 clearing the $1.41 consensus estimate by 3.39%, even as net sales of $4.35 billion came in essentially flat against expectations, up 4.1% year-over-year. The standout driver behind the earnings strength was Test and Measurement, which posted 14% reported sales growth and saw its adjusted segment EBITA margin expand sharply to 29.7% from 25.5% a year ago, underscoring the premium profitability of Emerson's evolving automation technology portfolio. Orders momentum remained a bright spot, with underlying orders growing 9% for the fourth consecutive quarter, led by demand from North America, India, and the Middle East and Africa. Institutional sentiment has been mixed, with some investors trimming positions even as others added exposure ahead of results. Looking ahead, Emerson guided for full-year net sales growth of approximately 5.5% and adjusted EPS of $6.40 to $6.55, with Q2 adjusted EPS expected in the $1.50 to $1.55 range and roughly $2.20 billion targeted for shareholder returns.
Key Takeaways
- • Fourth consecutive quarter of strong underlying orders growth at 9%
- • Robust demand for automation technology led by Software & Systems
- • Strength in North America, India, and the Middle East & Africa
- • Test & Measurement segment delivered 14% reported and 11% underlying sales growth
- • Adjusted segment EBITA margin of 27.7% despite 30 bps decline
EMR Forward Guidance & Outlook
For fiscal year 2026, Emerson expects net sales growth of approximately 5.5%, underlying sales growth of approximately 4%, GAAP EPS of $4.78–$4.93, and adjusted EPS of $6.40–$6.55. For Q2 2026, net sales growth is expected at 3%–4%, underlying sales growth of 1%–2%, GAAP EPS of $1.06–$1.11, and adjusted EPS of $1.50–$1.55. Full-year operating cash flow is projected at $4.0B–$4.1B, free cash flow of $3.5B–$3.6B, and approximately $1.0B in share repurchases. The company plans to return approximately $2.2B to shareholders through buybacks and dividends.
EMR YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
EMR Revenue by Segment
With YoY comparisons, source: SEC Filings
“Emerson met sales commitments and exceeded expectations for profitability as our global teams continue to execute well. We delivered a fourth consecutive quarter of strong underlying orders growth, and we are experiencing robust demand for our automation technology, led by Software & Systems, with strength in North America, India and the Middle East & Africa.”
— Lal Karsanbhai, Q1 2026 Earnings Press Release
EMR Earnings Trends
EMR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
EMR EPS Trend
Earnings per share: estimate vs actual
EMR Revenue Trend
Quarterly revenue: estimate vs actual
EMR Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $1.41 | $1.46 | +3.39% | $4.35B | -0.06% |
| Q4 25 BEAT FY | $1.62 | $1.62 | +0.00% | $4.86B | -0.99% |
| FY Full Year | $6.00 | $6.00 | +0.02% | $18.02B | -0.26% |
| Q3 25 BEAT | $1.51 | $1.52 | +0.48% | $4.55B | -1.19% |
| Q2 25 BEAT | $1.41 | $1.48 | +4.71% | $4.43B | +1.11% |